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Article
Associations between midlife chronic
conditions and medication use with anxiety
and depression: A cross-sectional analysis
of the PREVENT Dementia study
Lucy E Stirland1,2 , Sarah Gregory1,2, Tom C Russ1,2,3,4,
Craig W Ritchie1,2 and Graciela Muniz-Terrera1,2
Abstract
Background:Multimorbidity including physical and mental illness is increasing in prevalence. We aimed to investigate the
associations between physical conditions and medication use with anxiety and depression in midlife.
Methods: We conducted an observational cross-sectional study of volunteers in the PREVENT Dementia study. Using
logistic and linear regression, we investigated the association between increasing numbers of self-reported chronic
physical conditions and medications with self-reported depression and anxiety disorder, and scores on the Center for
Epidemiologic Studies Depression (CES-D) scale and Spielberger State-Trait Anxiety Inventory (STAI) state subtest.
Results: Of the 210 participants, 148 (71%) were women and 188 (90%) Caucasian. The mean age was 52 (standard
deviation (SD) ¼ 5.5) years. The mean number of physical conditions was 2.2 (SD ¼ 1.9) and medications 1.7 (SD ¼ 2.2).
Each additional physical condition was associated with increased odds of self-reported depression (odds ratio (OR) 1.41,
95% confidence interval (CI) 1.11–1.80; p ¼ 0.004, adjusted for age and gender) and anxiety disorder (OR 1.70, 95% CI
1.30–2.37; p < 0.001). Increasing medication use was associated with self-reported depression (adjusted OR per additional
medication 1.35, 95% CI 1.08–1.71; p ¼ 0.008) but not anxiety disorder. For each additional condition, CES-D scores
increased by 0.72 (95% CI 0.11–1.33; p ¼ 0.020) and for each extra medication, by 0.88 (95% CI 0.32–1.44; p ¼ 0.002).
There was no significant association between increasing conditions and medications with STAI scores. In models
accounting for antidepressant use, all associations were attenuated.
Conclusions: Having more physical conditions is associated with anxiety and depression in midlife, and taking more
medications is associated with depression but not anxiety.
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Introduction
Multimorbidity (the coexistence of multiple chronic dis-
eases) and polypharmacy (taking many different medica-
tions) are complex areas attracting increasing research and
policy attention.1 Although often linked with older age,
multimorbidity and polypharmacy are becoming more pre-
valent in midlife.2,3 Existing research shows that multimor-
bidity including both physical and mental illness is
common and associations between physical and mental
health are likely to be bidirectional.2,4
The evidence regarding the interplay between multimor-
bidity and depression or anxiety in midlife is limited. For
example, regarding depression, a recent systematic review
revealed that adults with multimorbidity had a three times
greater risk of depression than people with no chronic phys-
ical conditions.5 However, only one of the 40 studies
included in that review investigated a midlife cohort (aged
45–64 years), with 26 studies on older people and 13 on
adults of all ages, reflecting the fact that research on multi-
morbidity and polypharmacy tends to focus on older age
groups.6With regard to anxiety, cross-sectional studies have
shown that multimorbidity and anxiety coexist.7,8 There is
some evidence that increasing numbers of medication are
associated with more depressive symptoms, but this area is
less well understood.9 Furthermore, there is little research
into associations between polypharmacy and anxiety.
Midlife cohorts are increasingly studied in relation to the
early manifestations of neurodegenerative diseases that
may later lead to dementia. Identifying risk–disease inter-
actions may contribute to reducing incidence via risk mod-
ification strategies.10 Depression and anxiety in midlife
have been identified as risk factors for dementia,11,12
although the direction of the association remains uncer-
tain.13 Therefore, understanding the interplay between mul-
timorbidity and polypharmacy with depression and anxiety
is crucial, given the fact that all four have been associated
with poor brain health and dementia.
PREVENT Dementia is an ongoing cohort study
designed to investigate midlife risk factors for neurodegen-
erative diseases.14 It offers opportunities to explore the
associations between multimorbidity, polypharmacy,
depression and anxiety in midlife and to allow better under-
standing both of this age group and of future brain health.
Objective
We aimed to investigate whether increasing numbers of
chronic conditions and medications were associated with
depression and anxiety in this cross-sectional midlife cohort.
Methods
Participants
This is an observational cross-sectional study of a conve-
nience sample of volunteers in the first phase of PREVENT
Dementia (a dementia prevention study) in London, UK.
Volunteers were eligible to participate in PREVENT
Dementia if they were aged 40–59 years at baseline and
were fluent in English. Potential participants who reported
having cognitive impairment or dementia were excluded,
as were those with known contraindication to magnetic
resonance imaging (MRI). Recruitment took place through
a local database (DemReg),15 the UK-wide Join Dementia
Research database (JDR),16 via publicity online and at pub-
lic presentations. The DemReg and JDR databases are both
open to anyone aged 18 years and over who consent to be
contacted about research. Recruitment to DemReg was
facilitated via memory clinics, meaning those in the age
group of interest for this study were likely attending the
clinic as a family member of a patient. JDR is an online
database and, therefore, is available to anyone with Inter-
net access. These databases were selected as the major
recruitment tools for the study as they contained contact
details of volunteers meeting inclusion criteria who were
motivated to participate in research studies. The study
team aimed to recruit half of the participants with a family
history of dementia and half without. All participants gave
written informed consent and approval for the study was
given by the NHS Research Ethics Committee, Camber-
well St Giles. Participants underwent in-depth physical
and cognitive testing, comprehensive medical, lifestyle
and mental health questionnaires, brain MRI and fMRI
and provided neurodegenerative disease biomarkers.17
The study protocol is published in detail elsewhere,
including justification of the predefined minimum sample
size of 150 participants.14
Depression measures
Depressive symptoms were measured using the Center for
Epidemiologic Studies Depression (CES-D) scale.18 The
CES-D is a validated self-administered scale containing
20 questions about depressive symptoms and scored out
of 60. The questions cover mood, cognitive and somatic
symptoms of depressive disorder, and participants rate how
often they have experienced them in the past week (0¼ less
than 1 day, 1 ¼ 1–2 days, 2 ¼ 3–4 days and 3 ¼ 5–7 days).
Although a cut-off of 16 is generally used to identify
people with depression, the participant’s rating for each
item measures frequency of each reported symptom, so any
increase may be of clinical interest.19 In addition, even low
levels of psychological distress have been associated with
negative outcomes including mortality.20 We anticipated
that only a small proportion of this cohort of volunteers
would be classified as depressed so chose to analyse raw
scores as a pseudo-continuous variable. Participants’ self-
report of an active, current diagnosis of depression came
from the medical history, which was taken at interview by a
qualified doctor.
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Anxiety measures
Anxiety symptoms were measured using the Spielberger
State and Trait Anxiety Inventory (STAI) state subtest.21
It consists of 20 questions on symptoms of anxiety, scored
from one to four based on participants’ reported severity
(not at all, somewhat, moderately so and very much so)
resulting in a score between 20 and 80. A cut-off of 40
for clinically significant anxiety is frequently used,
although higher cut-offs have been shown to have higher
accuracy at detecting clinical anxiety disorders in older
people.22 As the STAI was originally designed as a contin-
uous scale and we were interested in symptoms, we again
used the overall score as a pseudo-continuous variable.
Participants’ self-report of current anxiety disorder was
taken from the medical history.
Chronic conditions
The PREVENT Dementia case report medical history
includes a list of medical conditions. Participants were
asked whether they had ever had each condition and
whether it was currently active. They also had the oppor-
tunity to report other conditions, which were recorded as
free text by the interviewing doctor. We reviewed all poten-
tial conditions and defined them as chronic if they were
likely to be present for at least six months, have an impact
on quality of life and have a pattern of recurrence or dete-
rioration. This definition was based on a combination of
definitions from the International Classification of Primary
Care, version 2 and from the NHS National Services Scot-
land Information Services Division.23,24 Depending on the
nature of each condition, some were included if they had
ever been diagnosed and others only if they were active.
We excluded psychiatric disorders due to their overlap with
our outcomes. This left 55 possible chronic physical con-
ditions, which are listed, with their duration definitions, in
Appendix 1. Multimorbidity is commonly defined as the
coexistence of two or more conditions and many studies
use dichotomous variables (e.g. 0–1 versus 2 conditions).
However, this approach does not capture the full distribu-
tion of conditions, particularly at the higher extremes.25
We, therefore, used continuous counts of conditions as
exposure variables for analyses.
Medication history
At the research interview, study doctors collected informa-
tion on current medication use according to participant
self-report. This included drug name, dose, frequency and
indication. The reported medications were then coded
according to theWorld Health Organization’s (WHO) Ana-
tomical Therapeutic Chemical (ATC) classification sys-
tem.26 Over-the-counter vitamins or health supplements
were excluded, as were entries with insufficient informa-
tion to generate an ATC code. Due to the likely effect of
antidepressant use on both depression and anxiety out-
comes, we excluded antidepressants from the total count
of medications. We aimed to account for anxiolytic medi-
cations but included them in the overall count. We used this
adjusted medication count as an exposure variable in
regression models.
Additional variables
Participants reported their age and gender, which we
included in all regression models as these are clinically
relevant factors influencing depression and anxiety symp-
toms. Use of antidepressants was both clinically relevant
and statistically significant in preparatory analyses. Con-
sidering that antidepressants are used for several indica-
tions, we reviewed the free text records on medication
indication and generated a variable for antidepressant use
for any psychiatric indication. We included this variable in
a separate adjusted model and tested for interaction effects
between chronic conditions and antidepressant use. We
conducted sensitivity analyses in a sample excluding parti-
cipants who took antidepressants for psychiatric indica-
tions. We also created a variable for using ATC-coded
anxiolytic medications.
Statistical analysis
All analyses were run in R version 3.4.3.27 We used Stu-
dent’s t-test to compare the mean age, chronic conditions
and medications between people with and without self-
reported depression and anxiety disorder. Linear regres-
sion models were used for the continuous outcome
variables (CES-D and STAI scores) and logistic regres-
sion for binary outcomes, namely, the presence of self-
reported depression and anxiety disorder. Owing to the
disproportionate gender split, we performed additional
analyses stratified by gender.
Results
Description of the sample
The sample, from the pilot phase of PREVENT Dementia
in London, UK, consisted of 210 individuals, 148 (70.5%)
of whom were women. The mean age was 52.0 (SD ¼ 5.5)
years and median 53 years. Self-reported race was Cauca-
sian for 89.5% of participants with the next largest groups
being Black (n ¼ 7, 3.3%) and Indian subcontinent (n ¼ 7,
3.3%). Almost half (103, 49.0%) of the participants had a
first-degree relative with dementia; 10 (4.8%) were current
smokers, 80 (38.1%) were ex-smokers and 120 (57.1%) had
never smoked. The mean weekly alcohol intake was 11.5
units (SD ¼ 12.4), and the mean body mass index was 27.7
kg/m2 (SD ¼ 5.3). The principal demographic details are
listed in Table 1. The mean number of chronic physical
conditions was 2.2 (SD ¼ 1.9), with a range of 0–9. The
mean number of medications reported was 1.7 (SD ¼ 2.2)
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and range 0–12. After excluding antidepressants, the
mean number of medications was 1.5 (SD ¼ 2.0). Only
one participant (0.5%) was taking an anxiolytic medica-
tion so due to low prevalence, this variable was not
included in further analyses. Appendix 1 lists all the
included conditions with their prevalence in this sample.
There were no missing data for any of the variables
included.
For participants with at least one chronic condition, the
mean number of medications per condition was 0.7 (SD
0.9). Among all participants, 119 (56.7%) had two or more
conditions and 48 (22.9%) people took three or more med-
ications (39 (18.6%) excluding antidepressants). There
was a statistically significant difference between the mean
number of chronic physical conditions among people with
and without self-reported depression (m1 ¼ 3.6, m2 ¼ 2.1;
p¼ 0.025) but not number of medications or age (Table 2).
For people with and without self-reported anxiety disor-
der, there was a difference in the mean number of chronic
conditions (m1 ¼ 4.2, m2 ¼ 2.0; p < 0.001) but not the
number of medications or age. Figure 1 shows box plots
of these distributions.
We found that 26 (12.4%) participants were taking anti-
depressants, of whom 18 (8.6%) were doing so for psychia-
tric indications. Within this group, 13 (72.2%) participants
reported a diagnosis of depression and 12 (66.7%) reported
anxiety disorder. We tested for interaction effects between
chronic conditions and antidepressant use and found no
statistically significant interaction. Table 3 presents the
characteristics of participants according to their antidepres-
sant status; there was a significantly higher rate of self-
reported depression and anxiety disorder among those
taking antidepressants for a psychiatric indication. People
taking antidepressants also had significantly higher mean
CES-D scores (m1 ¼ 14.3, m2 ¼ 8.7; p ¼ 0.021) and mean
chronic conditions (m1 ¼ 3.7, m2 ¼ 1.4; p ¼ 0.006).
Depression outcomes
On the CES-D, 35 (16.7%) participants scored 16 or over,
which is the accepted cut-off for depression. The mean
CES-D score was 9.2 (SD ¼ 8.1). Sixteen people (7.6%)
reported a diagnosis of depression in their medical history,
and of these, seven (44.0%) scored above the 16 cut-off
point on the CES-D. Nine (4.3%) participants reported both
depression and an anxiety disorder.
With each additional physical condition, the CES-D
score increased by 0.72 units (95% CI 0.11–1.33; p ¼
0.020) after adjustment for age and gender. However, the
estimate dropped below conventional significance levels
when we additionally adjusted for antidepressant use
(b ¼ 0.56, 95% CI 0.06–1.18; p ¼ 0.078) and in a
Table 1. Sample characteristics in whole sample (n ¼ 210).
Variable n (%) Mean (SD)
Gender (female) 148 (70.5)
Race (Caucasian) 188 (89.5)
Current depression (self-report) 16 (7.6)
Current anxiety disorder (self-report) 21 (10.0)
Taking antidepressant for any indication 26 (12.4)
Taking anxiolytic medication 1 (0.5)
Age (years) 52.0 (5.5)
Education (years) 15.9 (3.4)
CES-D Total (possible range 0–60) 9.2 (8.2)
STAI Total (possible range 20–80) 30.4 (9.4)
Number of chronic physical conditions 2.2 (1.9)
Number of current medications including antidepressants 1.7 (2.2)
Number of current medications excluding antidepressants 1.5 (2.0)
SD: standard deviation; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
Table 2. Characteristics of participants reporting depression or anxiety disorder.
No
depression
Self-reported
depression
p for difference
(Student’s t-test)
No anxiety
disorder
Self-reported
anxiety
disorder
p for difference
(Student’s t-test)
Mean age in years (SD) 52.0 (5.4) 51.3 (6.3) 0.642 52.0 (5.4) 51.4 (6.3) 0.656
Mean number of chronic physical
conditions (SD)
2.1 (1.8) 3.6 (2.5) 0.025 2.0 (1.6) 4.2 (2.4) <0.001
Mean number of medications taken
(excluding antidepressants) (SD)
1.4 (1.8) 2.7 (3.2) 0.140 1.4 (1.9) 2.2 (2.5) 0.174
SD: standard deviation; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
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subsample of participants who did not take antidepressants
for psychiatric indications (b ¼ 0.43, 95% CI 0.23–1.08;
p ¼ 0.199).
Similarly, although each additional medication emerged
as associated with higher CES-D scores (b ¼ 0.88, 95% CI
0.32–1.44; p ¼ 0.002, adjusted for age and gender), even
when including antidepressant use as a covariate (b¼ 0.74,
95% CI 0.18–1.31; p ¼ 0.011), testing the association in a
subsample of those not taking antidepressants rendered it
non-significant (b¼ 0.53, 95% CI0.09–1.16; p¼ 0.094).
The odds ratio (OR) for self-reported depression with
the number of chronic physical conditions, adjusted for age
and gender, was 1.41 (95% CI 1.11–1.80; p ¼ 0.004).
Additionally adjusting for antidepressant use reduced the
OR to 1.26 (0.83–1.90; p ¼ 0.273). The OR adjusted for
age and gender per unit increase in number of medications
Figure 1. Box plots of age, chronic conditions and medication for self-reported outcomes in whole sample (n ¼ 210).
Table 3. Characteristics of sample based on antidepressant status.
Not taking
antidepressant for
psychiatric indication
(n ¼ 192)
Taking
antidepressant for
psychiatric indication
(n ¼ 18)
Variable n (%) Mean (SD) n (%) Mean (SD)
p for difference
(Student’s t-test or 2 test)
Gender (female) 132 (68.8) 16 (88.9) 0.128
Race (Caucasian) 172 (89.6) 16 (88.9) 1
Current depression (self-report) 3 (1.6) 13 (72.2) <0.001
Current anxiety disorder (self-report) 9 (4.7) 12 (66.7) <0.001
Age (years) 51.9 (5.5) 52.1 (5.8) 0.907
Education (years) 15.9 (3.3) 16.5 (4.6) 0.575
CES-D Total (possible range 0–60) 8.7 (7.9) 14.3 (9.1) 0.021
STAI Total (possible range 20–80) 30.0 (9.4) 34.0 (9.1) 0.090
Number of chronic physical conditions 2.0 (1.8) 3.7 (2.2) 0.006
Number of current medications excluding antidepressants 1.4 (1.8) 2.9 (3.) 0.052
SD: standard deviation; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
Bold figure indicates p < 0.05.
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for self-reported depression was 1.35 (1.08–1.71; p ¼
0.008). This OR reduced to 1.13 (0.79–1.70; p ¼ 0.545)
when additionally adjusting for antidepressant use with
psychiatric indication.
Both increasing number of medications and increasing
chronic conditions were associated with increasing CES-D
score and self-reported depression. These associations were
attenuated when accounting for antidepressant use for psy-
chiatric indications and became no longer statistically sig-
nificant at conventional levels. All regression analysis
results are summarized in Table 4.
Anxiety outcomes
The mean score on the STAI was 30.4 (SD¼ 9.4). Twenty-
one participants (10%) reported a diagnosis of anxiety dis-
order in their medical history; of these, 7 (33.3%) scored
above the cut-off of 40 on the STAI and 18 had2 physical
conditions.
There were no significant associations between an
increasing number of chronic conditions and the STAI state
score in a model adjusted for age and gender (b ¼ 0.14,
95% CI 0.57–0.85; p ¼ 0.704). This remained non-
significant when additionally adjusting for antidepressant
use (b¼ 0.01, 95% CI0.72–0.73; p¼ 0.986). The regres-
sion coefficient for the effect of each additional medication
on the STAI score was b ¼ 0.27 (95% CI 0.39–0.92;
p ¼ 0.425) and this remained non-significant when adding
antidepressant use as a covariate (b¼ 0.16, 95% CI0.51–
0.83; p ¼ 0.637). In the subsample of participants who did
not take antidepressants for a psychiatric indication, the
associations between both chronic conditions and medica-
tion with STAI did not meet conventional significance lev-
els (presented as model 3 in Table 4).
The OR (95% CI) adjusted for age and gender for self-
reported anxiety disorder with number of chronic condi-
tions was 1.70 (1.35–2.19; p < 0.001). Additionally
adjusting for antidepressant use increased the OR to 1.73
(1.30–2.37; p < 0.001). The OR (95% CI) adjusted for age
and gender per unit increase in number ofmedications for self-
reported anxiety disorder was 1.23 (0.99–1.51; p ¼ 0.045).
This OR remained non-significant at 1.04 (0.78–1.36;
p¼ 0.800)when additionally adjusting for antidepressant use.
Analyses stratified by gender
The results of regression analyses stratified by gender are
presented in Appendix 2. Table 2A shows that in women,
there were associations between chronic physical condi-
tions and medications with CES-D scores and self-
reported depression. There were also associations between
conditions, but not medications, and self-reported anxiety
disorder. Additionally adjusting for antidepressant use ren-
dered the associations non-significant, apart from the
model including chronic conditions and self-reported anxi-
ety disorder. By contrast, in men, the only significant asso-
ciation was between increasing medication use and
increasing CES-D scores. Depression was reported by one
Table 4. Summary of regression analysis results.
Exposure
Outcome Model
Chronic physical conditions Medications excluding antidepressants
Coefficient
(95% CI) ORa (95% CI) p Value
Coefficient
(95% CI) ORa (95% CI)
p
Value
Depression
CES-D Model 1 0.72 (0.11, 1.33) 0.020 0.88 (0.32, 1.44) 0.002
Model 2 0.56 (0.06, 1.18) 0.078 0.74 (0.18, 1.31) 0.011
Model 3b 0.43 (0.23, 1.08) 0.199 0.53 (0.09, 1.16) 0.094
Self-reported depression Model 1 1.41 (1.11, 1.80) 0.004 1.35 (1.08, 1.71) 0.008
Model 2 1.26 (0.83, 1.90) 0.273 1.13 (0.79, 1.70) 0.545
Model 3b NA NA
Anxiety
STAI Model 1 0.14 (0.57, 0.85) 0.704 0.27 (0.39, 0.92) 0.425
Model 2 0.01 (0.72, 0.73) 0.986 0.16 (0.51, 0.83) 0.637
Model 3b 0.06 (0.71, 0.84) 0.871 0.20 (0.54, 0.95) 0.588
Self-reported anxiety
disorder
Model 1 1.70 (1.35, 2.19) <0.001 1.23 (0.99, 1.51) 0.045
Model 2 1.73 (1.30, 2.37) <0.001 1.04 (0.78, 1.36) 0.800
Model 3b NA NA
OR: odds ratio; CI: confidence interval; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
aOR per unit increase in number of chronic conditions or medications.
bN.B. smaller sample size, as below: model 1: whole sample (n ¼ 210), adjusted for age and gender; model 2: whole sample (n ¼ 210), adjusted for age,
gender and use of antidepressants for psychiatric indication; model 3: sample excluding participants taking antidepressants for psychiatric indication (n¼
192), adjusted for age and gender (not calculated for self-reported diagnoses of depression and anxiety disorder due to high proportion of people with
diagnoses taking medication).
Bold figure indicates p < 0.05.
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(1.6%) male participant and anxiety disorder by two
(3.2%) male participants, so we did not conduct analyses
with self-reported depression or anxiety disorder as out-
comes in men.
Figures 2 and 3 show the OR and 95% CI for self-
reported depression and anxiety per unit increase in chronic
conditions and medications, respectively.
In summary, no clear association between increasing
medication use and anxiety measures emerged. Chronic
conditions were associated with self-reported anxiety dis-
order but not increasing STAI scores.
Discussion
Key results
We found associations between increasing chronic condi-
tions and self-reported depression, increasing CES-D
scores and self-reported anxiety disorder, but not STAI
score. There were associations between increasing numbers
of medication with both self-reported depression and
increasing CES-D scores. There was no association
between increasing medication count and anxiety, either
self-reported or according to the STAI. The findings no
longer met conventional significance levels when adjusting
for antidepressant use, suggesting that a preexisting diag-
nosis with partial treatment may explain the observed
associations.
Comparison to existing literature
Participants in the initial wave of the PREVENT Dementia
study had a mean of 2.2 chronic physical conditions.
Recent publications in similar age groups found figures
of 0.8 chronic conditions in an English primary care cohort
and 1.2 chronic conditions in Scottish data.2,28 The appar-
ently above-average prevalence of multimorbidity in PRE-
VENT Dementia participants may reflect the self-report
method of gathering medical history.
The majority of PREVENT Dementia participants were
taking at least one medication and among those, the mean
number of medications taken was 2.6 (SD 2.2). In contrast,
a population-level analysis in one region of Scotland found
that among adults (mean age 50.1 years) prescribed any
medication, the mean was 4.4 prescribed medications.29
The PREVENT Dementia cohort reported more than would
be expected in terms of medical conditions but were receiv-
ing less than would be expected in terms of medication.
This could imply a population that is very observant of their
own health but reporting conditions not severe enough to
require treatment. This discrepancy is, therefore, likely due
to the use of volunteers in PREVENT Dementia.
It is difficult to compare multimorbidity studies when
there is disparity between the number of possible condi-
tions listed in each of them. Previous studies reviewing
prevalence estimates of multimorbidity using disease
counts have recommended using a list of at least 12
Figure 2. OR (95% CI) of self-reported outcomes with each additional chronic physical condition: whole sample (n ¼ 210). OR: odds
ratio; CI: confidence interval.
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conditions30 and between 25 and 75 conditions.31 Our list
of 55 conditions is likely to have been more sensitive than
those in previous similar studies, with the consequent risk
of over-estimation of multimorbidity.
We found an association between increasing number of
medications (excluding antidepressants) and scores on the
CES-D and self-reported depression. The only similar
study using this measure was published in 1989 and found
a similar association but did not account for antidepressant
use.9 There has also been an increase in the prevalence of
polypharmacy since then.3 There is little in the literature
about medication use and specific anxiety outcomes, so our
analyses are novel in this area.
A systematic review and meta-analysis of 40 articles
found an OR of 1.45 (95% CI 1.28–1.64; p < 0.001) for
depression with each additional condition, which our
analyses of self-reported depression support. All of the
articles reviewed used either a depression rating scale or
clinical diagnosis; none considered both.5 A very large
cross-sectional study of primary care patients with
depression and controls found that people with depres-
sion were more likely to have multimorbidity and that
this association was stronger in people with socioeco-
nomic deprivation.32 This was a representative sample
from primary care, but used routinely collected diagnos-
tic information from health records and symptom mea-
sures were not available. Our research builds on this
evidence by assessing both self-reported diagnoses and
symptom scales as outcomes.
There have been two cross-sectional studies specifically
exploring the link between multimorbidity and anxiety,
both of which found statistically significant associations.
One was a large international study of adults aged over 18
years, which measured multimorbidity from a list of nine
conditions and anxiety with a single question answered on a
5-point scale.7 The other measured anxiety according to the
Beck Anxiety Inventory and multimorbidity from a list of
seven conditions, in participants aged over 65 years.8
Again, there is strength in our research using both self-
reported diagnosis and symptom scales; we found a similar
association between increasing chronic conditions and
anxiety disorder but not symptoms as reported on STAI.
This difference between reported diagnosis and objective
measurement may reflect the fact that those who report a
diagnosis are likely to be receiving treatment and, there-
fore, report fewer active symptoms.
Strengths and limitations of this study
The complementary outcomes we examined include not
only validated rating scales but also participant-reported
clinical diagnoses. This selection of measures, therefore,
adds breadth compared to previous research in this area.
Furthermore, there is limited published work on multimor-
bidity and polypharmacy in midlife, so this work fills an
important gap.
The data available were collected in the baseline pilot
phase of PREVENT Dementia, only permitting exploratory
Figure 3. OR (95% CI) of self-reported outcomes with each additional medication: whole sample (n ¼ 210). OR: odds ratio; CI:
confidence interval.
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cross-sectional analyses of 210 participants. The cohort
was designed as a longitudinal study and follow-up data
collections are ongoing. Cross-sectional analysis leaves
questions about direction of causality unclear. It is known,
for example, that all mental disorders are associated with
later physical health consequences, so the findings from
this study may reflect reverse causality in that people who
were originally depressed experienced physical health
deterioration.33 The recruitment of volunteers who are
likely to have an interest in dementia research limits the
generalizability of our results. The sample is 89.5% Cau-
casian which is close to the UK proportion of 87.2% but
less diverse than the population of London where 59.8% of
people are white.34
Although the STAI and CES-D feature some questions
on somatic symptoms of anxiety and depression, the major-
ity are cognitive symptoms so this is unlikely to capture
physical symptoms of physical conditions. However, peo-
ple with anxiety and depression, particularly older people,
can report physical symptoms as the primary com-
plaint.35,36 This may lead to seeking medical attention and,
therefore, receiving more diagnoses of physical conditions.
The self-report nature of the PREVENT Dementia medical
history and the overlap between the clinical presentations
of depression and anxiety disorder meant that a number of
participants reported both conditions. The questions in the
screening tests mean that CES-D includes symptoms of
generalized anxiety disorder and STAI, symptoms of
depression.22,37 In addition, there is an overlap between
multimorbidity and polypharmacy and we did not adjust
for either when assessing each exposure.38
With such a sample size, groups within the data set can
be small, for example, only 26 participants reported current
use of antidepressant medication. There are also more
women (148, 70.5%) than men in the sample, so when
groups are subdivided by gender, they can become very
small – for example, only seven men took antidepressants.
It is important to recognize the role of chance in analyses
on these numbers, and effect size could be over-estimated.
In addition, we adjusted for covariates that were clinically
relevant and statistically significant in preparatory analyses
but there may be residual confounding from unmeasured
factors. These exploratory analyses will inform future
research in a larger sample from this cohort.
The nature of the PREVENT Dementia initial visit is
that all the medical history and medications are self-
reported. This can lead to several types of bias including
recall bias and social desirability bias.39 Self-reported
depression may be more sensitive than CES-D for identi-
fying people with a clinical diagnosis who have received
treatment and, therefore, perform better on testing than
they might have done untreated. However, participants
may also report depression that has not been clinically
diagnosed, more so perhaps than a physical condition.
Previous studies comparing self-report with diagnostic
or screening tests for depression have remarked upon this
complex relationship.40 Self-reported antidepressant use
in cohort studies, however, has been found to correlate
strongly with prescription records.41
In all but one analysis, an apparent association between
exposure and outcomes ceased when including antidepres-
sant use as a covariate. This implies that taking antidepres-
sants, perhaps as a marker for mental disorders (fully or
partially treated), is an important explanation in the path-
way between chronic conditions, medication use and anxi-
ety and depression. The overlap between physical and
mental illness is complex and difficult to capture but we
attempted to understand it by approaching it from several
different angles. This is a strength over previous research,
which has not attempted to account for the treatment of
depression or anxiety.5,7–9 In addition, antidepressant use
suggests a preexisting diagnosis of mental illness, but
detailed temporality of mental and physical diagnoses can-
not be ascertained in cross-sectional data. Future waves of
the PREVENT Dementia study will allow longitudinal
exploration of this issue.
Implications
The presence of associations between increasing chronic
conditions, medications and depression supports the
important interaction of physical health and resulting
medication burden with mental health, even in midlife.
The modest nature of these results in a small sample size
limits the certainty with which conclusions can be drawn
but reinforces the need to corroborate them in larger data
sets. A particular strength of completing this work in a
pilot wave of an ongoing longitudinal study is the oppor-
tunity to revisit the analyses when data from future waves
are available. In these cross-sectional analyses, we were
unable to evaluate the implications for participants’ future
development of dementia, but follow-up may allow this.
The focus on midlife individuals may also inform strate-
gies to improve health in later life. For example, if midlife
physical health can be optimized, this may reduce later
anxiety and depression.
Conclusions
In this cross-sectional study of a middle-aged cohort of
volunteers, we found associations between increasing
chronic conditions and self-reported depression, depressive
symptoms and self-reported anxiety disorder but not anxi-
ety symptoms. In addition, there were associations between
increasing number of medications and depression (both
self-reported and according to a screening scale) but not
anxiety. The use of antidepressants, as a marker for preex-
isting mental illness, attenuated the associations found.
This work adds to understanding of physical and mental
health multimorbidity.
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Appendix 1
Table 1A. List of included chronic physical conditions with prevalence in PREVENT Dementia baseline phase.
Condition Definition Prevalence, n (%)
Eye disease Currently active 113 (53.8)
Asthma Currently active 28 (13.3)
Migraine Currently active 27 (12.9)
Sleep disorder Currently active 25 (11.9)
Gastro-oesophageal reflux disease Currently active 23 (11.0)
Hypertension Currently active 22 (10.5)
Irritable bowel syndrome Currently active 17 (8.1)
Other musculoskeletal condition (each free text entry checked for relevance) Currently active or ever
recorded
17 (8.1)
Cardiac arrhythmia Currently active 14 (6.7)
Cancer Ever diagnosed 14 (6.7)
Osteoarthritis Currently active 26 (12.4)
(continued)
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Table 1A. (continued)
Condition Definition Prevalence, n (%)
Degenerative disc disease Currently active 13 (6.2)
Anaemia Currently active 12 (5.7)
Chronic constipation Currently active 12 (5.7)
Hypothyroidism Currently active 11 (5.2)
Diabetes Currently active 7 (3.3)
Peripheral vascular disease – venous Currently active 6 (2.9)
Other gastrointestinal disorder (each free text entry checked for relevance) Currently active or ever
recorded
5 (2.4)
Inflammatory bowel disease Ever recorded 4 (1.9)
Other genitourinary/reproductive disorder (each free text entry checked for
relevance)
Currently active or ever
recorded
4 (1.9)
Other haematological disorder (each free text entry checked for relevance) Currently active or ever
recorded
3 (1.4)
Cholelithiasis Currently active 3 (1.4)
Diverticulitis Currently active 3 (1.4)
Peripheral nerve disorder Currently active 3 (1.4)
Angina Currently active 2 (1.0)
Other cardiovascular disease (each free text entry checked for relevance) Currently active or ever
recorded
2 (1.0)
Peptic ulcer disease Currently active 2 (1.0)
Liver disease (excluding hepatitis) Currently active 2 (1.0)
Other eye disease (each free text entry checked for relevance) Currently active or ever
recorded
2 (1.0)
Gout Currently active 2 (1.0)
Stroke Ever diagnosed 2 (1.0)
Other neurological disorder (each free text entry checked for relevance) Currently active or ever
recorded
2 (1.0)
Valvular heart disease Currently active 1 (0.5)
Coronary artery disease Ever diagnosed 1 (0.5)
Gastrointestinal bleed Currently active 1 (0.5)
Benign prostatic hyperplasia Currently active 1 (0.5)
Nephrolithiasis Currently active 1 (0.5)
Hyperthyroidism Currently active 1 (0.5)
Other metabolic (each free text entry checked for relevance) Currently active or ever
recorded
1 (0.5)
Immune deficiency Currently active 1 (0.5)
Other immunological condition (each free text entry checked for relevance) Currently active or ever
recorded
1 (0.5)
Aortic aneurysm Ever diagnosed 0
Cholecystitis Currently active 0
Chronic obstructive pulmonary disease Ever diagnosed 0
Collagen vascular disease Currently active 0
Congenital heart disease Currently active 0
Congestive heart failure Ever diagnosed 0
Hepatitis Currently active 0
Kidney disorder Currently active 0
Pacemaker Ever reported 0
Pancreatitis Currently active 0
Parkinson’s disease Ever diagnosed 0
Peripheral vascular disease – arterial Currently active 0
Seizure/convulsion disorder Currently active 0
Tuberculosis Currently active 0
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Appendix 2
Results of supplementary analyses stratified by gender
Table 2B. Men only.a
Exposure
Outcome Model
Chronic physical conditions Medications excluding antidepressants
Coefficient (95% CI) p Value Coefficient (95% CI) p Value
Depression
CES-D Model 1 0.37 (1.01, 1.75) 0.592 1.10 0.22, 1.97) 0.015
Model 2 0.36 (1.09, 1.80) 0.622 1.10 (0.21, 2.00) 0.016
Anxiety
STAI Model 1 0.59 2.03, 0.84) 0.412 0.55 (0.41, 1.50) 0.256
Model 2 0.52 (2.02, 0.99) 0.492 0.60 (0.37, 1.57) 0.221
CI: confidence interval; CES-D: Centre for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory; model 1: men only (n¼ 62), adjusted
for age; model 2: men only (n ¼ 62), adjusted for age and use of antidepressants for psychiatric indication.
aSelf-reported depression and anxiety disorder not included owing to small number of male participants reporting these diagnoses.
Table 2A. Women only.
Exposure
Outcome Model
Chronic physical conditions Medications excluding antidepressants
Coefficient
(95% CI) ORa (95% CI) p Value
Coefficient
(95% CI) ORa (95% CI)
p
Value
Depression
CES-D Model 1 0.81 (0.12, 1.51) 0.021 0.74 (0.01, 1.48) 0.048
Model 2 0.62 (0.09, 1.32) 0.085 0.50 (0.25, 1.25) 0.190
Self-reported
depression
Model 1 1.43 (1.12, 1.84) 0.005 1.44 (1.12, 1.90) 0.005
Model 2 1.33 (0.88, 2.05) 0.177 1.25 (0.84, 2.06) 0.329
Anxiety
STAI Model 1 0.33 (0.50, 1.16) 0.436 0.10 (0.79, 0.98) 0.828
Model 2 0.16 (0.69, 1.02) 0.707 0.12 (1.03, 0.79) 0.795
Self-reported anxiety
disorder
Model 1 1.71 (1.34, 2.25) <0.001 1.25 (0.98, 1.58) 0.061
Model 2 1.72 (1.29, 2.40) <0.001 1.05 (0.79, 1.42) 0.732
OR: odds ratio; CI: confidence interval; CES-D: Center for Epidemiologic Studies Depression; STAI: State-Trait Anxiety Inventory.
aOR per unit increase in number of chronic conditions or medications: model 1: women only (n¼ 148), adjusted for age; model 2: women only (n¼ 148),
adjusted for age and use of antidepressants for psychiatric indication.
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